Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance

BridgeBio Pharma IncTrade
Royal Caribbean Cruises LtdTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Royal Caribbean Cruises Ltd — how do they compare? BridgeBio Pharma Inc trades at $83.61 (market cap $16.36B), while Royal Caribbean Cruises Ltd trades at $305.26 (market cap $82.15B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 5× BridgeBio Pharma Inc's market cap, and Royal Caribbean Cruises Ltd pays a 1.63% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIORCL
Market Cap
$16.36B$82.15B
Sector
HealthConsumer Cyclical
52-Week High
$90.17$365.84
52-Week Low
$47.29$246.71
Enterprise Value
$18.14B$104.79B
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.

The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.

Royal Caribbean Cruises Ltd

Royal Caribbean (RCL) trades at $308, down 3.75% today, as strong earnings growth and bullish technical signals are tempered by geopolitical concerns affecting European demand. The company reported Q2 2026 EPS of $4.21, beating estimates, and raised full-year guidance, with revenue reaching $17.93B in 2025. Technical analysis shows a bullish trend with support at $305 and resistance at $314, while fundamentals highlight robust profitability with a 23.54% net margin and 45.33% ROE.

RCL presents a compelling growth story with record bookings and fleet expansion through 2028, though risks include high debt levels, capital-intensive spending, and geopolitical volatility. Analyst consensus is bullish with a $343 price target, but investors should weigh strong cash flow generation against ongoing investment requirements and market sensitivity to economic cycles.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Royal Caribbean Cruises Ltd

Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.

Read more on RCL